Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(8):629-630; doi:10.1093/jnci/95.8.629
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Cappelletti, V.
Right arrow Articles by Daidone, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cappelletti, V.
Right arrow Articles by Daidone, M. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 8, 629-630, April 16, 2003
© 2003 Oxford University Press

CORRESPONDENCE

Re: Tamoxifen May Be an Effective Treatment for BRCA1-Related Breast Cancer Irrespective of Estrogen Receptor Status

Vera Cappelletti, Silvia Veneroni, Danila Coradini, Saro Oriana, Gorana Tomasic, Mamoun Younes, Maria Grazia Daidone

Affiliations of authors: V. Cappelletti, S. Veneroni, D. Coradini, M. G. Daidone (Department of Experimental Oncology, Unit 10), S. Oriana (Department of Surgery), G. Tomasic (Department of Pathology), Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; M. Younes, Department of Pathology, Baylor College of Medicine, Houston, TX.

Correspondence to: Maria Grazia Daidone, M.D., Department of Experimental Oncology, Unit 10, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy (e-mail: mariagrazia.daidone@istitutotumori.mi.it).

The first 10% of the full text of this article appears below.

The actual benefit of tamoxifen treatment in patients carrying BRCA1 mutations remains an open question due to contrasting clinical results. In fact, the outcome of retrospective analyses suggesting a protective effect of tamoxifen in preventing contralateral tumors was recently supported in a cohort of Ashkenazi Jewish breast cancer patients by the observation of a reduced risk . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CarcinogenesisHome page
A.-M. Simeone, C.-X. Deng, G. J. Kelloff, V. E. Steele, M. M. Johnson, and A. M. Tari
N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells
Carcinogenesis, May 1, 2005; 26(5): 1000 - 1007.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. J. Fabian and B. F. Kimler
Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer
J. Clin. Oncol., March 10, 2005; 23(8): 1644 - 1655.
[Full Text] [PDF]

Home page
 JCOHome page
B. N. Peshkin, C. Isaacs, C. Finch, S. Kent, and M. D. Schwartz
Tamoxifen As Chemoprevention in BRCA1 and BRCA2 Mutation Carriers With Breast Cancer: A Pilot Survey of Physicians
J. Clin. Oncol., December 1, 2003; 21(23): 4322 - 4328.
[Abstract] [Full Text] [PDF]